Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease

Shigeru Iwata, Kazuyoshi Saito, Kunihiro Yamaoka, Shizuyo Tsujimura, Masao Nawata, Kentaro Hanami, Yoshiya Tanaka

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

It is often difficult to manage refractory gastrointestinal tract complications of Behçet's disease (entero-BD) by conventional therapy. In this study, we assessed the short- and long-term efficacy and safety of the combination therapy of infliximab, an anti-tumor-necrosisfactor (TNF)-α antibody, and methotrexate in ten patients with refractory entero-BD refractory to conventional therapies. The short- (weeks) and long-term (by 2 years) effects of infliximab at 3-5 mg/kg body weight every 8 weeks on the clinical course and intestinal manifestations were assessed by abdominal computed tomography (CT) and colonoscopy. The primary endpoint was the rate of disappearance of ileocecal ulceration at 12 months of therapy. All patients showed improvement of gastrointestinal symptoms and disease-associated complications within 4 weeks. Furthermore, the rate of disappearance of ileocecal ulcerations was 50% (5/10 patients) at 6 months and 90% (9/10 patients) at 12 months, and, therefore 90% of patients were satisfied with the primary endpoint. Furthermore, corticosteroid dose was significantly reduced from 22.0 to 1.8 mg/day at 24 months. No severe adverse effects were observed during the 24 months of follow-up. We provide evidence for the rapid and excellent efficacy of infliximab in patients with refractory entero-BD and that the combination of infliximab and methotrexate brings about long-term alleviation of entero-BD and excellent tolerability.

Original languageEnglish
Pages (from-to)184-191
Number of pages8
JournalModern Rheumatology
Volume21
Issue number2
DOIs
Publication statusPublished - 2011 Apr
Externally publishedYes

Fingerprint

Neoplasm Antibodies
Methotrexate
Therapeutics
Gastrointestinal Diseases
Colonoscopy
Gastrointestinal Tract
Infliximab
Adrenal Cortex Hormones
Tomography
Body Weight
Safety

Keywords

  • Entero-Behçet's disease
  • Inflammatory bowel disease
  • Infliximab
  • MTX
  • TNF-α

ASJC Scopus subject areas

  • Rheumatology

Cite this

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. / Iwata, Shigeru; Saito, Kazuyoshi; Yamaoka, Kunihiro; Tsujimura, Shizuyo; Nawata, Masao; Hanami, Kentaro; Tanaka, Yoshiya.

In: Modern Rheumatology, Vol. 21, No. 2, 04.2011, p. 184-191.

Research output: Contribution to journalArticle

Iwata, Shigeru ; Saito, Kazuyoshi ; Yamaoka, Kunihiro ; Tsujimura, Shizuyo ; Nawata, Masao ; Hanami, Kentaro ; Tanaka, Yoshiya. / Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. In: Modern Rheumatology. 2011 ; Vol. 21, No. 2. pp. 184-191.
@article{c7f2c0281aca456b85cf9be28489ef12,
title = "Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Beh{\cc}et's disease",
abstract = "It is often difficult to manage refractory gastrointestinal tract complications of Beh{\cc}et's disease (entero-BD) by conventional therapy. In this study, we assessed the short- and long-term efficacy and safety of the combination therapy of infliximab, an anti-tumor-necrosisfactor (TNF)-α antibody, and methotrexate in ten patients with refractory entero-BD refractory to conventional therapies. The short- (weeks) and long-term (by 2 years) effects of infliximab at 3-5 mg/kg body weight every 8 weeks on the clinical course and intestinal manifestations were assessed by abdominal computed tomography (CT) and colonoscopy. The primary endpoint was the rate of disappearance of ileocecal ulceration at 12 months of therapy. All patients showed improvement of gastrointestinal symptoms and disease-associated complications within 4 weeks. Furthermore, the rate of disappearance of ileocecal ulcerations was 50{\%} (5/10 patients) at 6 months and 90{\%} (9/10 patients) at 12 months, and, therefore 90{\%} of patients were satisfied with the primary endpoint. Furthermore, corticosteroid dose was significantly reduced from 22.0 to 1.8 mg/day at 24 months. No severe adverse effects were observed during the 24 months of follow-up. We provide evidence for the rapid and excellent efficacy of infliximab in patients with refractory entero-BD and that the combination of infliximab and methotrexate brings about long-term alleviation of entero-BD and excellent tolerability.",
keywords = "Entero-Beh{\cc}et's disease, Inflammatory bowel disease, Infliximab, MTX, TNF-α",
author = "Shigeru Iwata and Kazuyoshi Saito and Kunihiro Yamaoka and Shizuyo Tsujimura and Masao Nawata and Kentaro Hanami and Yoshiya Tanaka",
year = "2011",
month = "4",
doi = "10.1007/s10165-010-0370-y",
language = "English",
volume = "21",
pages = "184--191",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease

AU - Iwata, Shigeru

AU - Saito, Kazuyoshi

AU - Yamaoka, Kunihiro

AU - Tsujimura, Shizuyo

AU - Nawata, Masao

AU - Hanami, Kentaro

AU - Tanaka, Yoshiya

PY - 2011/4

Y1 - 2011/4

N2 - It is often difficult to manage refractory gastrointestinal tract complications of Behçet's disease (entero-BD) by conventional therapy. In this study, we assessed the short- and long-term efficacy and safety of the combination therapy of infliximab, an anti-tumor-necrosisfactor (TNF)-α antibody, and methotrexate in ten patients with refractory entero-BD refractory to conventional therapies. The short- (weeks) and long-term (by 2 years) effects of infliximab at 3-5 mg/kg body weight every 8 weeks on the clinical course and intestinal manifestations were assessed by abdominal computed tomography (CT) and colonoscopy. The primary endpoint was the rate of disappearance of ileocecal ulceration at 12 months of therapy. All patients showed improvement of gastrointestinal symptoms and disease-associated complications within 4 weeks. Furthermore, the rate of disappearance of ileocecal ulcerations was 50% (5/10 patients) at 6 months and 90% (9/10 patients) at 12 months, and, therefore 90% of patients were satisfied with the primary endpoint. Furthermore, corticosteroid dose was significantly reduced from 22.0 to 1.8 mg/day at 24 months. No severe adverse effects were observed during the 24 months of follow-up. We provide evidence for the rapid and excellent efficacy of infliximab in patients with refractory entero-BD and that the combination of infliximab and methotrexate brings about long-term alleviation of entero-BD and excellent tolerability.

AB - It is often difficult to manage refractory gastrointestinal tract complications of Behçet's disease (entero-BD) by conventional therapy. In this study, we assessed the short- and long-term efficacy and safety of the combination therapy of infliximab, an anti-tumor-necrosisfactor (TNF)-α antibody, and methotrexate in ten patients with refractory entero-BD refractory to conventional therapies. The short- (weeks) and long-term (by 2 years) effects of infliximab at 3-5 mg/kg body weight every 8 weeks on the clinical course and intestinal manifestations were assessed by abdominal computed tomography (CT) and colonoscopy. The primary endpoint was the rate of disappearance of ileocecal ulceration at 12 months of therapy. All patients showed improvement of gastrointestinal symptoms and disease-associated complications within 4 weeks. Furthermore, the rate of disappearance of ileocecal ulcerations was 50% (5/10 patients) at 6 months and 90% (9/10 patients) at 12 months, and, therefore 90% of patients were satisfied with the primary endpoint. Furthermore, corticosteroid dose was significantly reduced from 22.0 to 1.8 mg/day at 24 months. No severe adverse effects were observed during the 24 months of follow-up. We provide evidence for the rapid and excellent efficacy of infliximab in patients with refractory entero-BD and that the combination of infliximab and methotrexate brings about long-term alleviation of entero-BD and excellent tolerability.

KW - Entero-Behçet's disease

KW - Inflammatory bowel disease

KW - Infliximab

KW - MTX

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=79960139513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960139513&partnerID=8YFLogxK

U2 - 10.1007/s10165-010-0370-y

DO - 10.1007/s10165-010-0370-y

M3 - Article

C2 - 21052764

AN - SCOPUS:79960139513

VL - 21

SP - 184

EP - 191

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 2

ER -